Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Mr. Stanislas Veillet

Market Cap

8.06 Million EUR

Sector

Healthcare

Website

https://www.biophytis.com

Description

Biophytis S.A.

Read More

Overview

Value

12

Growth

35

Health

22

Management

50

Analyst Opinion

51

Total

34

All Scores Out Of 100

Best Features

  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • Earnings growth has slowed down recently
  • Income is not covering expenditure and investment
  • Earnings are negative
  • There is a history of diluting shareholders
  • Has a high level of debt
  • Poor overall financial health
  • No margin of safety at their current market price
  • Poor earnings and cashflow growth
  • Cashflow is growing faster than revenue

Market Peers

ALBPS.PA

Key Figures

PE Ratio (TTM)

N/A

Margin Of Safety (DCF)

-18.37%

Revenue Growth (5 Year Average)

N/A

Ratings Consensus

Neutral

Share Buybacks

-106.34%

Dividend Yeild (TTM)

N/A

Valuation

Value Score

12

  • Estimated intrinsic-value of 31.84 undefined EUR is lower than current price ( 39.50 undefined EUR)
  • Free-cashflow-yeild of -211.02% is worse than the market average (4.7%)
  • Margin-of-safety of -18.37% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: N/A

Current Price: 0 EUR

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

N/Ax

Free Cashflow Yeild

-211.02%

PE/Earnings Growth

N/A

Price/Book

1.39x

Growth

Growth Score

35

  • Revenue growth has improved this yeara
  • 5 Year Average Earnings growth of 15.84% is higher than the market average (14.48%)
  • 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
  • Earnings growth has slowed this year
  • 5 Year Average Free Cashflow growth of 0.74% is lower than the market average (12.35%)
  • Free Cashflow growth has slowed this year

Revenue Growth

N/A

Earnings Growth

15.84%

Cashflow Growth

0.74%

Health

Health Score

22

  • Assets cover liabilities
  • Normal operation does not require debt to be sustainable
  • Cashflow is negative
  • Has a high level of debt
  • Debt repayments significantly impact cashflow

Altman Z Score

N/A

Piostroski Score

N/A

Debt/Equity

2.70x

Current Assets/Liabilities

1.37x

Free Cashflow/Total Debt

N/Ax

Debt/Capital

0.49x

Management

Management Score

50

  • Has issued new shares to finance growth when share price is high
  • Return-on-capital-employed of -44.09% is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity
  • Return-on-equity of -929.56% is lower than the market average (15%)

Average Buybacks/Dilution

-106.34%

Recent Buybacks/Dilution

72.44%

5 Year Price Volitility

79.74%

Return On Assets

-146.24%

Return On Capital Employed

-44.09%

Return On Equity

-929.56%

Return On Free Cashflow

526.21%

Return On Investments

-4045.09%

Analysts

Analyst Opinion

51

  • Ratings consensus is Neutral

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Biophytis S.A.

Currency

EUR

Beta

1.34745

Vol Avg

2426308

Ceo

Mr. Stanislas Veillet

Cik

Cusip

F52042102

Exchange

Paris

Full Time Employees

26

Industry

Biotechnology

Sector

Healthcare

Ipo Date

2015-07-13

Address

14 avenue de l'Opera

City

Paris

State

ILE-DE-FRANCE

Country

FR

Zip

75005

Phone

33141836600

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies